Peter D Friedmann1, Donna Wilson2, Randall Hoskinson2, Michael Poshkus2, Jennifer G Clarke2. 1. University of Massachusetts Medical School-Baystate and Baystate Health, Springfield, MA, United States; Rhode Island Hospital, Providence, RI, United States; Thundermist Health Center, Warwick, RI, United States; The Rhode Island Department of Corrections, Cranston, RI, United States; Warren Alpert Medical School of Brown University, Providence, RI, United States. Electronic address: peter.friedmannmd@bhs.org. 2. University of Massachusetts Medical School-Baystate and Baystate Health, Springfield, MA, United States; Rhode Island Hospital, Providence, RI, United States; Thundermist Health Center, Warwick, RI, United States; The Rhode Island Department of Corrections, Cranston, RI, United States; Warren Alpert Medical School of Brown University, Providence, RI, United States.
Abstract
BACKGROUND: Opioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose. Initiation of extended release injectable naltrexone (XR-NTX)) prior to prison release might decrease relapse among opioid-dependent persons. OBJECTIVE: This pilot study examined the feasibility and acceptability of XR-NTX injection prior to prison release among adult inmates with opioid use disorder, followed by six months of community XR-NTX treatment. It sought to determine effects on treatment retention and abstinence compared to post-release XR-NTX initiation. METHODS: Recruitment for the study took place at the RIDOC's Adult Correctional Institute (ACI). Volunteers with a history of opioid dependence and a release date scheduled within 1-2months were self-referred in response to recruitment fliers. Consented volunteers were randomized to XR-NTX treatment prior to release followed by 5 monthly treatments in the community (pre-release) or six XR-NTX treatments in the community (post-release). RESULTS: Of 26 volunteers consented, 15 were randomized (9 pre-release, 6 post-release). The pre-release group generally had better treatment retention: 100% received the first NTX injection (vs. 67% post-release), 78% received more than one injection (vs. 17%) and 22% received all 6 injections (vs. 0%). The pre-release group also had greater abstinence, with a higher proportion of self-reported opioid free days in the first month after release (83% vs. 46%, fewer positive urine drug tests in the 6months after release (22% vs. 33%), and more days of opioid receptor blockade during the first two weeks after release, a high risk time for overdose death. CONCLUSIONS: Initiation of XR-NTX injection prior to release from prison might be an effective approach to reduce relapse to opioids, but these findings require confirmation in a larger trial.
RCT Entities:
BACKGROUND: Opioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose. Initiation of extended release injectable naltrexone (XR-NTX)) prior to prison release might decrease relapse among opioid-dependent persons. OBJECTIVE: This pilot study examined the feasibility and acceptability of XR-NTX injection prior to prison release among adult inmates with opioid use disorder, followed by six months of community XR-NTX treatment. It sought to determine effects on treatment retention and abstinence compared to post-release XR-NTX initiation. METHODS: Recruitment for the study took place at the RIDOC's Adult Correctional Institute (ACI). Volunteers with a history of opioid dependence and a release date scheduled within 1-2months were self-referred in response to recruitment fliers. Consented volunteers were randomized to XR-NTX treatment prior to release followed by 5 monthly treatments in the community (pre-release) or six XR-NTX treatments in the community (post-release). RESULTS: Of 26 volunteers consented, 15 were randomized (9 pre-release, 6 post-release). The pre-release group generally had better treatment retention: 100% received the first NTX injection (vs. 67% post-release), 78% received more than one injection (vs. 17%) and 22% received all 6 injections (vs. 0%). The pre-release group also had greater abstinence, with a higher proportion of self-reported opioid free days in the first month after release (83% vs. 46%, fewer positive urine drug tests in the 6months after release (22% vs. 33%), and more days of opioid receptor blockade during the first two weeks after release, a high risk time for overdose death. CONCLUSIONS: Initiation of XR-NTX injection prior to release from prison might be an effective approach to reduce relapse to opioids, but these findings require confirmation in a larger trial.
Authors: Daniel Wolfe; M Patrizia Carrieri; Nabarun Dasgupta; Alex Wodak; Robert Newman; R Douglas Bruce Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Peter D Friedmann; Randall Hoskinson; Michael Gordon; Robert Schwartz; Timothy Kinlock; Kevin Knight; Patrick M Flynn; Wayne N Welsh; Lynda A R Stein; Stanley Sacks; Daniel J O'Connell; Hannah K Knudsen; Michael S Shafer; Elizabeth Hall; Linda K Frisman Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Michael S Gordon; Timothy W Kinlock; Frank J Vocci; Terrence T Fitzgerald; Asli Memisoglu; Bernard Silverman Journal: J Subst Abuse Treat Date: 2015-07-18
Authors: Ryan D McDonald; Babak Tofighi; Eugene Laska; Keith Goldfeld; Wanda Bonilla; Mara Flannery; Nadina Santana-Correa; Christopher W Johnson; Neil Leibowitz; John Rotrosen; Marc N Gourevitch; Joshua D Lee Journal: Contemp Clin Trials Date: 2016-05-10 Impact factor: 2.226
Authors: Joshua D Lee; Ryan McDonald; Ellie Grossman; Jennifer McNeely; Eugene Laska; John Rotrosen; Marc N Gourevitch Journal: Addiction Date: 2015-04-05 Impact factor: 6.526
Authors: Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice Journal: J Subst Abuse Treat Date: 2019-01-26
Authors: Ali Jalali; Philip J Jeng; Daniel Polsky; Sabrina Poole; Yi-Chien Ku; George E Woody; Sean M Murphy Journal: J Subst Abuse Treat Date: 2022-07-02
Authors: Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman Journal: Addiction Date: 2018-03-24 Impact factor: 6.526
Authors: Kathleen M Carroll; Charla Nich; Tami L Frankforter; Sarah W Yip; Brian D Kiluk; Elise E DeVito; Mehmet Sofuoglu Journal: Drug Alcohol Depend Date: 2018-10-04 Impact factor: 4.492